NEWS Australian Prescriber New Release: October Issue
New Release: Australian Prescriber October Issue
PUBLISHED: 14 October 2025
Explore the
Australian Prescriber issue:
Volume 48 Issue 5.
The October issue of Australian Prescriber highlights the management of attention deficit hyperactivity disorder (ADHD) in children and adolescents.
In Australia, approximately one in 20 children have ADHD with rates ranging from 6% to 10% in children and adolescents. ADHD is a common neurodevelopmental disorder in young people,
and it can significantly disrupt home and school life. Drug treatment is recommended for children with persistent, substantial ADHD symptoms that do not respond to nondrug approaches.
Stimulants, such as methylphenidate, dexamfetamine and lisdexamfetamine, are the main drugs used for children with ADHD.
Further to this, the October issue delivers essential insights for healthcare professionals on how to select and use oral anticoagulants for atrial fibrillation (AF)
and venous thromboembolism (VTE), new Australasian consensus recommendations for gestational diabetes, and sun protection as a vital preventive health strategy.
The October issue features:
Australian Prescriber Podcast
The
Australian Prescriber Podcast is an easy way to stay in the know,
as it dives into some of the many great articles that
Australian Prescriber features every two months. Listen to recent episodes on
Choosing a nonsteroidal anti-inflammatory drug for pain and
Potentially inappropriate medicines for older people.
Claim CPD hours with Australian Prescriber
RACGP members can now easily claim CPD hours for all
Australian Prescriber articles and podcast episodes published in 2025.
Whether you’re catching up on clinical insights or listening on the go, your learning counts. Log your CPD hours by reading the
October issue of Australian Prescriber.
Join the 100,000 + healthcare professionals who trust and rely on
Australian Prescriber.
Subscribe now for free.